The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors
Craig L. Garthwaite
American Economic Journal: Applied Economics, 2012, vol. 4, issue 3, 116-37
Despite dramatic improvements in medical technology, little attention has been paid to the role of these innovations in improving economic outcomes. This study estimates the labor supply effects of Cox-2 inhibitors, a widely prescribed class of pharmaceuticals used for the treatment of chronic pain and inflammation and primarily marketed under the brand names Vioxx, Celebrex, and Bextra. This paper exploits the removal of Vioxx from the market in 2004 as an exogenous change in drug use. This removal was associated with a 0.35 percentage point decrease in overall labor force participation and $19 billion in lost wages. (JEL I12, J22, L65, O31).
JEL-codes: I12 J22 L65 O31 (search for similar items in EconPapers)
Note: DOI: 10.1257/app.4.3.116
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (10) Track citations by RSS feed
Downloads: (external link)
Access to full text is restricted to AEA members and institutional subscribers.
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:aea:aejapp:v:4:y:2012:i:3:p:116-37
Ordering information: This journal article can be ordered from
Access Statistics for this article
American Economic Journal: Applied Economics is currently edited by Alexandre Mas
More articles in American Economic Journal: Applied Economics from American Economic Association Contact information at EDIRC.
Bibliographic data for series maintained by Michael P. Albert ().